SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-060583
Filing Date
2024-05-15
Accepted
2024-05-15 17:08:01
Documents
73
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q alrn-20240331.htm   iXBRL 10-Q 1161443
2 EX-10.1 alrn-ex10_1.htm EX-10.1 97146
3 EX-10.2 alrn-ex10_2.htm EX-10.2 10090
4 EX-10.3 alrn-ex10_3.htm EX-10.3 34535
5 EX-31.1 alrn-ex31_1.htm EX-31.1 15817
6 EX-31.2 alrn-ex31_2.htm EX-31.2 16058
7 EX-32.1 alrn-ex32_1.htm EX-32.1 7761
8 EX-32.2 alrn-ex32_2.htm EX-32.2 7771
  Complete submission text file 0000950170-24-060583.txt   6364362

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT alrn-20240331.xsd EX-101.SCH 1167248
76 EXTRACTED XBRL INSTANCE DOCUMENT alrn-20240331_htm.xml XML 826902
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Aileron Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

IRS No.: 134196017 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38130 | Film No.: 24952453
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)